Breakpoint localization within the M-bcr and clinical course do not correlate in patients with chronic myelogenous leukemia undergoing alfa interferon therapy.
The breakpoint localization was analyzed in 61 patients with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia to compare the breakpoint localization and clinical course. All patients were treated with interferon alfa (IFN alpha) or IFN alpha plus IFN gamma at the time of the study. Thirty-three of the patients had been pretreated with other cytostatic drugs. Sixty-nine per cent of the breakpoints were located in the 5' region of the major breakpoint cluster region (M-bcr), 29% in the 3' part. There was no significant difference between these two groups with respect to response to IFN(s), clinical course or conversion to blast crisis, nor survival.
Opalka
B
B
Institute of Molecular Biology, University of Essen, Germany.
Wandl
U
U
Beer
U
U
Roggenbuck
U
U
Kloke
O
O
Niederle
N
N
D002873:Chromosome Fragility; D002874:Chromosome Mapping; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D005810:Multigene Family; D011379:Prognosis; D011994:Recombinant Proteins; D012074:Remission Induction; D015996:Survival Rate
D004273:DNA, Neoplasm; D007370:Interferon Type I; D011994:Recombinant Proteins